Aspergillus Fumigatus (Asp f 8) IgE

If you have asthma that keeps flaring, or a lung condition that never quite settles, one question is whether your immune system has become allergic to a mold that floats in almost everyone's air. That mold is Aspergillus fumigatus. In a minority of people with asthma or cystic fibrosis, an allergic reaction to it inside the airways drives repeated flare-ups and lasting airway damage, and finding that reaction early can change how it's treated.

This test measures the allergy antibody against Asp f 8, one protein from that mold. It is a research-stage component measurement. Almost all the clinical evidence comes from tests against the whole mold extract or against other single proteins, so a result here is best read as one piece of a larger set.

One Protein Out of Many

IgE is the antibody class behind allergies. When your immune system decides a harmless protein is a threat, it makes IgE shaped to fit that protein, and that IgE sits on immune cells, ready to set off inflammation the next time you breathe the protein in.

Aspergillus fumigatus makes many proteins that can provoke IgE. The standard mold allergy test mixes them together as a whole-mold extract. Component tests measure one purified protein at a time. Asp f 8 is a P2 ribosomal protein from inside the fungal cell. Ribosomes are the machinery cells use to build proteins.

Most component research has focused on Asp f 1, 2, 3, 4, and 6. Those have published accuracy data for diagnosing allergic lung disease. Asp f 8 hasn't been studied the same way, and there are no validated disease cutpoints for it, so it can't classify ABPA by itself.

A positive result does show that your immune system has made IgE that recognizes this protein. Asp f 8 is generally treated as a cross-reactive allergen, though. P2 ribosomal proteins are highly conserved across many fungi, and humans make a similar one, so a positive result may partly reflect reactions to related proteins from other fungi rather than a specific Aspergillus allergy.

Allergic Bronchopulmonary Aspergillosis

The main reason anyone checks Aspergillus IgE is allergic bronchopulmonary aspergillosis, or ABPA. In ABPA, the mold grows in thick mucus inside the airways of someone with asthma or cystic fibrosis, and the immune system mounts a strong allergic attack on it. Left untreated, that cycle can permanently widen and scar the airways. That damage is called bronchiectasis.

IgE against the whole mold extract is the standard first screen. In adults with asthma, studies put sensitivity around 98 to 100 percent and specificity around 65 to 70 percent. That means a negative whole-mold result is fairly reassuring, while a positive whole-mold result needs more context.

Single-protein tests were developed to sharpen that. In a pooled analysis of studies, IgE against Asp f 4 or Asp f 6 correctly cleared about 99 out of 100 people without ABPA, and Asp f 1 or Asp f 3 caught about 97 out of 100 cases. In a Japanese study of sensitized patients, Asp f 1 and Asp f 2 did the best job of separating ABPA from simple sensitization. Those figures belong to those proteins, and Asp f 8 hasn't been tested the same way.

What this means for you: a positive Asp f 8 result on its own doesn't diagnose ABPA, and a negative one doesn't rule it out. The diagnosis rests on a combination of findings, which the last section walks through.

Harder-to-Control Asthma

Being allergic to Aspergillus tends to go with tougher asthma, even without full ABPA. In a study of 79 adults with asthma and 14 healthy controls, the asthma patients sensitized to the mold had lung function averaging 68% of the expected value, against 88% in the asthma patients who weren't sensitized. Among 318 people with difficult-to-treat asthma, sensitized patients had more symptoms, needed more treatment, and had worse airway function. Both studies measured sensitization to the whole mold, and neither looked at Asp f 8.

Within ABPA, a higher starting level of whole-mold IgE predicted more flare-ups. Among 149 people with newly diagnosed ABPA, those with the highest initial levels were more likely to relapse within a year.

If your asthma needs repeated courses of steroid tablets, mold sensitization is worth knowing about, because it points toward a driver that has its own treatment.

COPD and Bronchiectasis

The same pattern shows up beyond asthma. COPD is the long-term lung disease most often caused by smoking. Bronchiectasis can develop on its own from many causes, not only ABPA. The studies below measured whole-mold sensitization or other recombinant components, so they shouldn't be read as direct evidence for Asp f 8.

Sources: Tiew et al. 2022; Luo et al. 2025; Tiew et al. 2025.

What this means for you: the COPD study is the clearest sign that protein-level testing can find something the whole-mold test misses, though it relied on better-studied components. If you live with COPD or bronchiectasis and keep ending up on antibiotics or in hospital, Aspergillus sensitization is one treatable explanation worth checking.

Cystic fibrosis follows a similar logic. In people with cystic fibrosis who were sensitized to Aspergillus, a controlled inhaled dose of the mold allergen set off measurable allergic inflammation in their airways and made the airways more twitchy.

When Results Can Be Misleading

A single component result can mislead in a few predictable ways.

• Cross-reaction with other fungi or similar proteins: Asp f 8 belongs to a highly conserved protein family and is generally regarded as cross-reactive. A positive result may reflect related proteins from other fungi, and older research found cross-reaction with similar human P2 protein in sensitized people.
• Different methods and labs: the measurement method for this test isn't specified, and component results from different platforms or labs aren't interchangeable. If you ever compare two results, use the same lab.
• Sensitization without disease: plenty of people with asthma make IgE to Aspergillus and never develop ABPA. A positive result marks an immune response, and the condition itself needs other evidence.
• Allergy signal, not fungal burden: this blood test doesn't measure mold growing in your lungs. Culture, imaging, IgG, and the rest of the ABPA workup answer different questions.
• Lab interference: as with any antibody-based test, unusual antibodies in a sample can occasionally distort the result.

Should You Repeat It?

For most people, one result is enough. Mold-specific IgE changes little with treatment, so it isn't used to follow disease. A repeat mainly makes sense if an earlier result was negative and your breathing has since gotten worse.

Whole-mold IgE turns out to be a poor tracker. In 81 people treated for ABPA, eight weeks of steroids cut total IgE roughly in half while whole-mold specific IgE barely moved, and in about half of them it went slightly up. That's why specialists follow total IgE instead.

Single-protein IgE may behave differently, though the evidence is early. In a 2026 study of 122 people with ABPA, IgE against Asp f 1, Asp f 2, and Asp f 4 fell during treatment, and Asp f 4 IgE rose consistently during flare-ups. Whether Asp f 8 tracks disease the same way hasn't been shown.

What to Do With a Positive Result

A positive result is a reason to fill in the rest of the picture: total IgE, whole-mold Aspergillus IgE, IgE to the better-studied components, a blood eosinophil count, Aspergillus IgG, and a high-resolution chest CT scan. Eosinophils are the white blood cells that drive allergic inflammation. Aspergillus IgG is a second antibody type that reflects ongoing contact with the fungus.

• Positive here, everything else quiet: most likely sensitization or cross-reaction. There's no need to keep repeating it, but if your breathing changes, check the full set again.
• Positive whole-mold IgE plus high total IgE: this is the pattern current guidelines use to flag possible ABPA, and the next steps are eosinophils, Aspergillus IgG, and a chest CT.
• Add high eosinophils, positive IgG, or mucus plugging or widened airways on CT: this combination is how ABPA is diagnosed, and it needs specialist care.

ABPA is treated with prescription drugs, usually oral steroids or the antifungal itraconazole, so that's the point to bring in a pulmonologist or allergist. You can order the blood work yourself and arrive with the full set, which makes the first visit far more productive. If you have COPD or bronchiectasis with frequent flare-ups, the same blood panel plus spirometry is a sensible place to start. Spirometry is a breathing test.